Exciting developments at the ASH Annual Meeting and Exposition

The 66th ASH Annual Meeting and Exposition will be held from 7–10 December 2024, in San Diego, California, with an online component. As the most extensive event in the field of hematology, this gathering offers unparalleled opportunities for learning, networking, and innovation. Participants can explore hundreds of sessions focusing on the latest trends and research in the discipline.

The event begins with preview days on 4 and 5 December, where attendees can familiarise themselves with the virtual platform, review session details, and customise their schedules. This virtual experience provides a comprehensive look at the programme and ensures participants can maximise their engagement during the main event.

Programming officially kicks off on 6 December with workshops, symposia, and trainee events. Notable activities include interactive discussions on emerging scientific developments, training sessions for program directors, and the highly anticipated ASH-a-Palooza, which offers mentorship and career development opportunities exclusively for trainees. Networking sessions such as the Trainee Welcome Reception add to the vibrant atmosphere, fostering connections among professionals in the field.

From 7–10 December, the main meeting schedule is packed with diverse offerings. There are oral abstract sessions, scientific symposia, and product presentations by industry leaders. Attendees can participate in career development lunches, special interest workshops, and interactive sessions such as “How I Treat” for clinically relevant discussions. Poster sessions and exhibitions also provide a platform to explore innovative research and new products in the hematology sector.

Highlights include the prestigious Ham-Wasserman Lecture, the Plenary Scientific Session, and the ASH Awards, recognising outstanding contributions to the field. Networking lounges, such as the Trainee Lounge, offer relaxed spaces for informal meetings and discussions. Complementing the in-person experience, the virtual platform ensures that all participants can revisit session recordings and catch up on content after the event.

The meeting concludes on 10 December, with virtual catch-up days from 11–13 December. These days provide access to recorded presentations and poster sessions, allowing attendees to reflect on and absorb the wealth of information shared during the meeting.

The ASH Annual Meeting continues to set the benchmark for educational and professional excellence in hematology. Whether attending in person or virtually, participants can look forward to a rich programme designed to inspire and advance the field.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

AI-powered drug discovery is changing the future of medicine

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for

Poolbeg receives US patent for Immunomodulator development

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Poolbeg Pharma awarded POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision

AI in Pharmaceuticals

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

Poolbeg Pharma’s Oral GLP-1R agonist for metabolic disease

Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut regions and enter systemic circulation, targeting